AAD Licensed Content

The talk reviewed psoriasis topical therapy, emphasizing that topicals remain a cornerstone of care but are often limited by regimen complexity and poor adherence. Traditional treatments like topical steroids,…

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

New Topical Therapies for Psoriasis and the Definition of Topical Failure

Description

The talk reviewed psoriasis topical therapy, emphasizing that topicals remain a cornerstone of care but are often limited by regimen complexity and poor adherence. Traditional treatments like topical steroids, vitamin D analogs, calcineurin inhibitors, and keratolytics remain useful, though steroids require caution because of side effects with prolonged use. The speaker then highlighted two newer FDA-approved nonsteroidal agents: roflumilast, a PDE4 inhibitor available as cream and foam, and tapinarof, an AhR modulator available as cream. Both are once-daily and showed similar efficacy in trials, but roflumilast offers more vehicle flexibility and strong data for scalp and intertriginous disease with good tolerability, while tapinarof has the advantage of a durable remittive effect after discontinuation but can cause more irritation and folliculitis. The speaker shared practical preferences, such as using roflumilast for hair-bearing areas and tapinarof when treatment durability is a priority. The second half addressed undertreatment and defined topical failure: patients who cannot achieve clear or nearly clear skin after two consecutive four-week topical courses, especially those with extensive disease, high-impact sites, or meaningful quality-of-life impairment, should be considered candidates for systemic therapy. The overall message was to use topicals thoughtfully, recognize when they are insufficient, and avoid prolonged undertreatment.

View more

Conclusions

  • Topical therapy remains a cornerstone of psoriasis care, but it is often too complex and burdensome for patients to use consistently.
  • Poor adherence is common with topical regimens, and treatment complexity and dosing frequency are major contributors.
  • Roflumilast and tapinarof are effective newer non-steroidal topical options that expand treatment choices beyond older agents.
  • Roflumilast is especially useful for scalp, hair-bearing, and intertriginous areas because it comes in both cream and foam formulations and is generally well tolerated.
  • Tapinarof offers similar short-term efficacy to roflumilast, but its key advantage is a durable remittive effect after treatment is stopped.
  • Tapinarof may be less practical for some body sites because it is only available as a cream and can cause more irritation and folliculitis.
  • Choice between the new topicals should be driven by body site, vehicle preference, tolerability, need for scalp delivery, and whether off-treatment durability is a priority.
  • Many patients remain undertreated with topicals alone even when disease burden suggests they should be receiving systemic therapy.
  • Topical failure should be recognized as a formal reason to escalate psoriasis treatment rather than waiting for obvious widespread disease.
  • A practical definition of topical failure is inability to reach clear or nearly clear skin after two consecutive four-week topical courses.
  • Patients with high-impact sites or major quality-of-life impairment may warrant systemic therapy even when overall body surface area is low.
  • Greater attention to topical failure and undertreatment should improve treatment selection and patient outcomes in psoriasis.
  • JAMA. 2020 May 19;323(19):1945-1960.
  • Skin Res Technol. 2024;30(9):e70041.
  • J Am Acad Dermatol. 2021 Feb;84(2):432-470.
  • Curr Opin Rheumatol. 2024 Jul 1;36(4):289-294.
  • Front Pharmacol. 2018;9:1048.
  • J of Skin. 2021;5(6):s42.
  • J Am Acad Dermatol. 2024;91(2):273-280.
  • JAMA Dermatol. 2025 Jul 1;161(7):698-706.
  • J Am Acad Dermatol. 2021 Apr;84(4):1059-1067.
  • J Psoriasis Psoriatic Arthritis. 2024;10(1):22–27.